FDA Advisory Committee Unanimously Recommends First mRNA Flu Vaccine

A new era in seasonal respiratory protection cleared a critical regulatory hurdle on Thursday. The Food and Drug Administration's top vaccine advisory committee voted unanimously to recommend the first-ever mRNA-based influenza vaccine for adults aged 50 and older.[1][2]

The 9-0 vote by the Vaccines and Related Biological Products Advisory Committee marks a significant milestone for Moderna's investigational shot, branded as mFlusiva. If the FDA follows the panel's recommendation by its August 5 deadline, the vaccine could be deployed as early as the 2026-2027 winter flu season.[3][7]

The core advantage of the mRNA platform lies in its speed. Traditional influenza vaccines are primarily cultivated in chicken eggs—a cumbersome process that requires health officials to guess which flu strains will circulate up to six months in advance.[2][8]

Because the flu virus constantly mutates—a process known as antigenic drift—this long lead time frequently results in a mismatch between the vaccine and the virus that actually strikes in the winter.[2][6]

Messenger RNA technology bypasses the egg-based incubation entirely. Instead of injecting a weakened virus, the vaccine delivers microscopic genetic instructions that teach the body's cells how to produce the flu virus's hemagglutinin proteins, triggering a targeted immune response.[5][6]

This synthetic manufacturing process shrinks the production timeline from six months down to just two or three months. Public health officials argue this operational advantage could allow strain selection to occur much closer to the start of flu season, drastically reducing the risk of a mismatched vaccine and potentially preventing thousands of hospitalizations.[1][4]

The committee's endorsement was anchored by data from the Phase 3 Fluent trial, which enrolled over 40,000 adults across 11 countries.[3][5]

According to the data published in The New England Journal of Medicine, the mRNA-1010 vaccine demonstrated a relative vaccine efficacy of 26.6 percent against protocol-defined influenza-like illness when compared to standard-dose flu shots in adults 50 and older.[4][5]

The trial also indicated that the mRNA platform produced a longer-lasting immune response and generated antibodies capable of recognizing a broader range of flu strains than current traditional vaccines.[1][5]

However, the path to the committee's unanimous vote was unusually turbulent, highlighting significant debates over clinical trial design and shifting regulatory standards.[3][7]

In February 2026, the FDA issued a rare refusal-to-file letter, initially blocking Moderna's application. The agency's reviewers argued that the Phase 3 trial was not adequately controlled because it measured the mRNA shot against a standard-dose seasonal flu vaccine.[3][4]

For adults aged 65 and older, the Centers for Disease Control and Prevention typically recommends high-dose, recombinant, or adjuvanted vaccines, which provide stronger protection for aging immune systems. Critics within the FDA argued that comparing the new premium mRNA shot to a standard-dose baseline in seniors artificially inflated its perceived efficacy.[4][6]

The rejection sparked a brief but intense public dispute. Moderna countered that FDA staff had previously agreed to the standard-dose comparator during the trial's design phase. Following a formal meeting and public pushback, the FDA reversed course just weeks later and accepted the application.[3][8]

To bridge this evidence gap, the FDA and Moderna agreed to a bifurcated regulatory pathway. The company is seeking standard full approval for adults aged 50 to 64, where the standard-dose comparator is clinically appropriate.[4][7]

For the more vulnerable 65-and-older demographic, Moderna is seeking accelerated approval. This pathway requires the company to conduct a massive Phase 4 post-marketing confirmatory study, expected to enroll up to 800,000 participants over two flu seasons, to directly compare the mRNA vaccine against the high-dose shots currently dominating the senior market.[3][7]

On the safety front, FDA reviewers noted no severe adverse events, but flagged that the mRNA vaccine's reactogenicity is notably higher than that of traditional flu shots.[2][4]

Participants receiving the mRNA vaccine reported a 76 percent rate of solicited adverse events—such as injection-site pain, fever, fatigue, and muscle aches—compared to just 47 percent among those who received the standard flu shot. The FDA noted that these temporary reactions are typical of the mRNA platform, mirroring the side-effect profile seen during the COVID-19 rollout.[4][8]

Despite the elevated rate of temporary side effects and the lingering questions about high-dose comparisons, the advisory panel concluded that the overarching benefits of a highly adaptable, rapidly manufactured flu vaccine outweighed the risks.[1][7]

As the FDA prepares its final decision, the medical community is watching closely. If approved, mFlusiva will not only offer a new layer of respiratory protection but will also validate the mRNA platform's commercial and clinical viability far beyond the pandemic that first brought it to global prominence.[5][6]